SCHEMBL10099129

SCHEMBL10099129

CCOC(=O)CC(C)(N)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.43
MGAM O43451 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
ALDH1A1 P00352 4/20 0.40
TRPA1 O75762 1/20 0.40
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 1/20 0.38
HSD11B1 P28845 1/20 0.36
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
LMNA P02545 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 2/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15346514 1.00 GAA (0.43) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL11861490 0.81 GAA (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2741021 0.79 GAA (0.46) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL9711562 0.79 TSHR (0.39) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL23779364 0.79 GAA (0.50) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL1409293 0.79 GAA (0.50) GAAMGAMSIMGAM2ALDH1A1
Hydrochloric Acid SCHEMBL944681 0.77 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL29233778 0.77 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL974467 0.76 GAA (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL4007750 0.76 GAA (0.52) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739100-B2 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2023-08-29 US disclosed
US-11739100-B2 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2023-08-29 US disclosed
US-11739100-B2 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2023-08-29 US disclosed
CN-104603113-B Novel 2, 3-dihydro-1H-imidazo {1,2-a } pyrimidin-5-one and 1,2,3, 4-tetrahydropyrimidino {1,2-a } pyrimidin-6-one derivatives comprising substituted morpholines, preparation thereof and pharmaceutical use thereof 赛诺菲 2020-01-21 CN disclosed
US-20190292205-A1 Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2019-09-26 US disclosed
US-20190292205-A1 Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2019-09-26 US disclosed
US-10253043-B2 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2019-04-09 US disclosed
US-10253043-B2 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2019-04-09 US disclosed
US-20150148328-A1 Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2015-05-28 US disclosed
US-20150148328-A1 Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2015-05-28 US disclosed
US-20150148328-A1 Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof SANOFI (FR) 2015-05-28 US disclosed
EP-2864295-A2 NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2015-04-29 EP disclosed
EP-2655375-B1 PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF SANOFI SA (FR) 2014-12-03 EP disclosed
US-8815853-B2 Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2014-08-26 US disclosed
US-8815853-B2 Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof SANOFI (FR) 2014-08-26 US disclosed
WO-2013190510-A2 NOVEL 2,3-DIHYDRO-1H-IMIDAZO{1,2-a}PYRIMIDIN-5-ONE and this1,2,3,4-TETRAHYDROPYRIMIDO{1,2-a}PYRIMIDIN-6-ONE DERIVATIVES COMPRISING A SUBSTITUTED MORPHOLINE, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2013-12-27 WO disclosed
US-20130289031-A1 PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2013-10-31 US disclosed
US-20130289031-A1 PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2013-10-31 US disclosed
WO-2012085244-A1 PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF SANOFI (FR) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148328-A1 Novel 2,3-Dihydro-1H-imidazopyrimidin-5-one and this 1,2,3,4-tetrahydropyrimidopyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof RDX, MTX1, CCNY GAA 3622/4885MGAM 4242/4885SI 4477/4885
US-10253043-B2 2,3-dihydro-1H-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof MTX1, RDX, MTX2 GAA 2972/4885MGAM 4307/4885SI 4625/4885
US-11739100-B2 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives comprising a substituted morpholine, preparation thereof and pharmaceutical use thereof CBR3, MTX1, CBR1 GAA 3130/4885MGAM 4291/4885SI 4489/4885
US-20130289031-A1 PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF DPYD, TYMP, DHPS GAA 912/4885MGAM 4477/4885SI 2493/4885
US-20190292205-A1 Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof CCNY, CBR3, CBR1 GAA 2906/4885MGAM 4397/4885SI 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.